千红制药(002550) - 2021 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2021 was ¥495,364,573.66, a decrease of 2.55% compared to the same period last year[3]. - Net profit attributable to shareholders for Q3 2021 was ¥100,772,230.50, an increase of 22.15% year-on-year[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses decreased by 32.21% to ¥52,019,983.96 compared to the same period last year[3]. - Total operating revenue for the current period reached ¥1,368,373,802.06, an increase of 17.66% compared to ¥1,163,039,382.00 in the previous period[27]. - Total operating costs amounted to ¥1,205,103,296.49, up from ¥997,750,421.88, reflecting a growth of 20.82%[27]. - Operating profit for the current period was ¥216,698,009.41, compared to ¥176,494,913.97 in the previous period, indicating an increase of 22.77%[27]. - Net profit attributable to the parent company was ¥189,922,248.33, up from ¥146,207,871.88, representing a growth of 29.93%[30]. - Basic earnings per share increased to ¥0.1522 from ¥0.1198, reflecting a growth of 27.06%[30]. - The total comprehensive income for the current period was ¥183,962,056.50, compared to ¥135,817,681.36, reflecting an increase of 35.38%[30]. Assets and Liabilities - The company's total assets at the end of Q3 2021 were ¥2,370,051,473.27, a decrease of 3.33% from the end of the previous year[3]. - Total current assets decreased to ¥1,493,529,085.82 from ¥1,557,024,075.58 year-over-year[19]. - Non-current assets totaled ¥876,522,387.45, down from ¥894,755,338.00 in the previous year[19]. - Total liabilities decreased to ¥261,507,962.80 from ¥386,351,466.61, a reduction of 32.38%[23]. - The total equity attributable to shareholders increased to ¥2,129,041,649.31 from ¥2,079,989,811.74, a growth of 2.36%[23]. Cash Flow - Cash flow from operating activities for the year-to-date was ¥7,063,071.14, a significant decrease of 96.80% compared to the same period last year[3]. - Cash inflow from operating activities totaled 1,486,651,144.16 yuan, an increase from 1,323,763,641.67 yuan in the previous period, representing a growth of approximately 12.3%[33]. - Cash outflow from operating activities was 1,479,588,073.02 yuan, compared to 1,102,867,429.96 yuan in the previous period, indicating a significant increase of about 34.2%[33]. - The net cash flow from operating activities was 7,063,071.14 yuan, a decrease from 220,896,211.71 yuan in the previous period[33]. - Cash inflow from investment activities was 465,145,846.67 yuan, down from 902,175,928.88 yuan, reflecting a decline of approximately 48.5%[36]. - Cash outflow from investment activities totaled 321,211,073.04 yuan, compared to 549,714,384.25 yuan in the previous period, showing a decrease of about 41.5%[36]. - The net cash flow from investment activities was 143,934,773.63 yuan, down from 352,461,544.63 yuan, indicating a decline of approximately 59.1%[36]. - Cash inflow from financing activities was 37,006,125.44 yuan, significantly lower than 496,415,327.66 yuan in the previous period, a decrease of about 92.6%[36]. - The net cash flow from financing activities was -149,699,278.54 yuan, an improvement from -344,881,477.13 yuan in the previous period[36]. - The ending balance of cash and cash equivalents was 528,478,815.55 yuan, compared to 429,637,786.00 yuan in the previous period, reflecting an increase of approximately 23.1%[36]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 54,164[11]. - The largest shareholder, Wang Yaofang, holds 19.96% of the shares, totaling 255,402,000 shares[11]. - The company has a plan for employee stock ownership, with significant shares held by key stakeholders[11]. Research and Development - Research and development expenses increased by ¥10,980,600.00 due to ongoing investments in R&D projects[6]. - Research and development expenses for the current period were ¥44,031,958.91, slightly up from ¥43,247,674.11, indicating a focus on innovation[27]. Other Income - The company received government subsidies amounting to ¥8,968,113.23 for the year-to-date, contributing to other income[5]. - The company reported a decrease in other comprehensive income, with a net amount of -¥23,917.76 compared to -¥924,760.34 in the previous period[30]. Market Strategy - The company is exploring new strategies for market expansion and product development[18].